finanzen.net
22.05.2019 02:02
Bewerten
(0)

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027 | Nachricht | finanzen.net
DRUCKEN

NEW YORK, May 21, 2019 /PRNewswire/ --

Viral Vector & Plasmid DNA Manufacturing Market: Overview
This report analyzes the current and future scenario of the global viral vector & plasmid DNA manufacturing market for the period 2019 to 2027. Increase in prevalence and incidence rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with rare disorders, and raised acceptance for comparatively newer treatment options in developing countries are likely to be major drivers of the global viral vector & plasmid DNA manufacturing market during the forecast period.



Read the full report: https://www.reportlinker.com/p05775478/?utm_source=PRN



The viral vector & plasmid DNA manufacturing market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market.It also provides information and data analysis of the global market with respect to segments based on type, application, disease, end-user, and region.

A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section.Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market.

The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the viral vector & plasmid DNA manufacturing market.

Viral Vector & Plasmid DNA Manufacturing Market: Key Segments
Based on type, the global viral vector & plasmid DNA manufacturing market has been segmented into lentivirus, adenovirus, adeno-Associated Virus (AAV), plasmid DNA, and others.In terms of application, the global viral vector & plasmid DNA manufacturing market has been divided into gene therapy, vaccinology, and others.

Based on disease, the market has been segregated into genetic disorders, cancer, infectious disease, and others.In terms of end-user, the market has been bifurcated into biotech companies and research institutes.

The market size and forecast for each of these segments have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year.

Viral Vector & Plasmid DNA Manufacturing Market: Regional Outlook
In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report
The report also profiles major players operating in the global viral vector & plasmid DNA manufacturing market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza. The global viral vector & plasmid DNA manufacturing market has been segmented as below:

Viral Vector & Plasmid DNA Manufacturing Market, by Type
Lentivirus
Adenovirus
Adeno-Associated Virus (AAV)
Plasmid DNA
Others

Viral Vector & Plasmid DNA Manufacturing Market, by Application
Gene Therapy
Vaccinology
Others

Viral Vector & Plasmid DNA Manufacturing Market, by Disease
Genetic Disorders
Cancer
Infectious Disease
Others
Viral Vector & Plasmid DNA Manufacturing Market , by End-user
Biotech Companies
Research Institutes

Viral Vector & Plasmid DNA Manufacturing Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
GCC Countries
Rest of Middle East & Africa

Read the full report: https://www.reportlinker.com/p05775478/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/viral-vector-and-plasmid-dna-manufacturing-market---global-industry-analysis-size-share-growth-trends-and-forecast-2019---2027-300854438.html

SOURCE Reportlinker

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt tiefer -- Dow schließt kaum verändert -- Trump kritisiert Fed erneut -- Daimler-Aktie: Gewinnwarnung -- Lufthansa mit neuer Dividendenpolitik -- Dürr, METRO, MorphoSys, VW im Fokus

Bristol-Myers kämpft um grünes Licht für Celgene-Übernahme. Porsche ruft fast 100.000 Autos in USA zurück. Apple wehrt sich vor EU-Kommission gegen Spotify-Vorwürfe. RWE-Aktie nach HSBC-Abstufung unter Druck. Bitcoin hält sich in Sichtweite zu 11.000 US-Dollar. Trump kündigt neue Sanktionen gegen den Iran an.

Die 5 beliebtesten Top-Rankings

Promis
Diese Sternchen haben ihren eigenen Aktien-Index
Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das niedrigste Gehalt
Welche Branchen man besser meiden sollte.
DIe innovativsten Unternehmen
Diese Unternehmen sind am fortschrittlichsten
mehr Top Rankings

Umfrage

Die USA suchen Verbündete gegen den Iran. Sollte sich Deutschland einer solchen Allianz anschließen?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Daimler AG710000
Wirecard AG747206
Deutsche Bank AG514000
Microsoft Corp.870747
NEL ASAA0B733
TeslaA1CX3T
Amazon906866
Barrick Gold Corp.870450
Apple Inc.865985
Infineon AG623100
BayerBAY001
Lufthansa AG823212
CommerzbankCBK100
Volkswagen (VW) AG Vz.766403
Beyond MeatA2N7XQ